These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Klöppel G Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112 [TBL] [Abstract][Full Text] [Related]
4. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Janson ET; Sorbye H; Welin S; Federspiel B; Grønbæk H; Hellman P; Ladekarl M; Langer SW; Mortensen J; Schalin-Jäntti C; Sundin A; Sundlöv A; Thiis-Evensen E; Knigge U Acta Oncol; 2014 Oct; 53(10):1284-97. PubMed ID: 25140861 [TBL] [Abstract][Full Text] [Related]
5. Advances in the cytologic diagnosis of gastroenteropancreatic neuroendocrine neoplasms. Sigel CS Cancer Cytopathol; 2018 Dec; 126(12):980-991. PubMed ID: 30485690 [TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895 [TBL] [Abstract][Full Text] [Related]
7. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101 [TBL] [Abstract][Full Text] [Related]
8. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Tang LH; Basturk O; Sue JJ; Klimstra DS Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015 [TBL] [Abstract][Full Text] [Related]
9. Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma. Thomas KEH; Voros BA; Boudreaux JP; Thiagarajan R; Woltering EA; Ramirez RA Oncologist; 2019 Aug; 24(8):1076-1088. PubMed ID: 30635447 [TBL] [Abstract][Full Text] [Related]
10. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Eads JR; Halfdanarson TR; Asmis T; Bellizzi AM; Bergsland EK; Dasari A; El-Haddad G; Frumovitz M; Meyer J; Mittra E; Myrehaug S; Nakakura E; Raj N; Soares HP; Untch B; Vijayvergia N; Chan JA Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37184955 [TBL] [Abstract][Full Text] [Related]
11. Treatment of metastatic disease in patients with neuroendocrine tumors. Niederhuber JE; Fojo T Surg Oncol Clin N Am; 2006 Jul; 15(3):511-33, viii. PubMed ID: 16882495 [TBL] [Abstract][Full Text] [Related]
12. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors. Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study. Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205 [TBL] [Abstract][Full Text] [Related]
20. Gastroenteropancreatic neuroendocrine tumors. Where are we now? Castellano D Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():1. PubMed ID: 21365184 [No Abstract] [Full Text] [Related] [Next] [New Search]